Market closedNon-fractional

Esperion Therapeutics/ESPR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Esperion Therapeutics

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Ticker

ESPR

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Ann Arbor, United States

Employees

-

ESPR Metrics

BasicAdvanced
$447M
Market cap
-
P/E ratio
-$0.69
EPS
0.89
Beta
-
Dividend rate
$447M
0.89
2.222
1.709
-170.863
-186.502
-0.59%
-6.94%
27.73%
1.292
-1.51
-1.51
-10.846
183.74%
-79.63%
-0.57%
-50.78%

What the Analysts think about ESPR

Analyst Ratings

Majority rating from 8 analysts.
Buy

ESPR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
44.29% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$138M
327.64%
Net income
$61M
-208.35%
Profit margin
44.29%
-125.33%

ESPR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 627.27%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.46
-$0.37
-$0.50
$0.34
-
Expected
-$0.61
-$0.43
-$0.48
$0.05
-$0.18
Surprise
-24.75%
-14.40%
3.63%
627.27%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Esperion Therapeutics stock?

Esperion Therapeutics (ESPR) has a market cap of $447M as of July 06, 2024.

What is the P/E ratio for Esperion Therapeutics stock?

The price to earnings (P/E) ratio for Esperion Therapeutics (ESPR) stock is 0 as of July 06, 2024.

Does Esperion Therapeutics stock pay dividends?

No, Esperion Therapeutics (ESPR) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Esperion Therapeutics dividend payment date?

Esperion Therapeutics (ESPR) stock does not pay dividends to its shareholders.

What is the beta indicator for Esperion Therapeutics?

Esperion Therapeutics (ESPR) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Esperion Therapeutics stock

Buy or sell Esperion Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing